Croban’s Amgen AMGN Stock Holding History

Croban’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Buy	4,078 +94	+2%	+$32.2K	0.65%	39
2026 Q1	$1.4M	Buy	3,984 +24	+0.6%	+$8.56K	0.66%	41
2025 Q4	$1.3M	Buy	3,960 +73	+2%	+$23.2K	0.62%	42
2025 Q3	$1.1M	Buy	3,887 +6	+0.2%	+$1.74K	0.73%	46
2025 Q2	$1.08M	Buy	3,881 +58	+2%	+$16.4K	0.93%	44
2025 Q1	$1.19M	Sell	3,823 -3	-0.1%	-$886	1.1%	32
2024 Q4	$997K	Buy	+3,826	New	+$1.14M	0.98%	40
2023 Q4	$997K	Buy	+3,826	New	+$1.04M	0.99%	40

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Croban's AMGN Position: Q2 2026 in Review

Croban increased its Amgen (AMGN) stake by 2.4% in Q2 2026, buying an estimated $32.2K and bringing the position to 4,078 shares worth $1.48M. The position accounts for 0.65% of the portfolio, ranked #39.

Croban first reported a position in AMGN in Q4 2023 and has held it in 8 quarters since. 3,156 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Croban held 4,078 shares of Amgen worth $1.48M as of Q2 2026.
Croban bought 94 Amgen shares in Q2 2026, an estimated $32.2K.
Amgen made up 0.65% of Croban's portfolio in Q2 2026, its #39 holding.
Croban first reported a position in Amgen in Q4 2023 and has held it in 8 quarters since.
3,156 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Croban's 13F filing for Q2 2026, filed 3 Aug 2026.